923-33.
210. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J,
Buchbinder M, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superﬁcial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the
RESILIENT randomized trial. J Endovasc Ther 2012;19:1-9.
211. Matsumura JS, Yamanouchi D, Goldstein JA, Pollock CW,
Bosiers M, Schultz GA, et al. The United States StuDy for

JOURNAL OF VASCULAR SURGERY
Volume 61, Number 3S

EvalUating EndovasculaR TreAtments of Lesions in the Superﬁcial
Femoral Artery and Proximal Popliteal By usIng the Protege EverfLex NitInol STent SYstem II (DURABILITY II). J Vasc Surg
2013;58:73-83.e1.
212. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al.
Sustained safety and effectiveness of paclitaxel-eluting stents for
femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013;61:
2417-27.
213. Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M,
Mueller-Huelsbeck S, et al. Heparin-bonded covered stents versus
bare-metal stents for complex femoropopliteal artery lesions: the
randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superﬁcial femoral artery occlusive disease).
J Am Coll Cardiol 2013;62:1320-7.
214. Johnston PC, Vartanian SM, Runge SJ, Hiramoto JS